169 related articles for article (PubMed ID: 9626031)
1. Malignant hyperthermia and central core disease: disorders of Ca2+ release channels.
Loke J; MacLennan DH
Am J Med; 1998 May; 104(5):470-86. PubMed ID: 9626031
[No Abstract] [Full Text] [Related]
2. Haplotype analysis of the BYR1 gene in malignant hyperthermia and central core disease.
Quane KA; Keating KE; Healy JM; Heffron JJ; Lehane M; Krivosic-Horber R; Heytens L; McCarthy TV
Biochem Soc Trans; 1995 May; 23(2):372S. PubMed ID: 7672403
[No Abstract] [Full Text] [Related]
3. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
[TBL] [Abstract][Full Text] [Related]
4. Should patients with central core disease be screened for malignant hyperthermia?
Halsall PJ; Bridges LR; Ellis FR; Hopkins PM
J Neurol Neurosurg Psychiatry; 1996 Jul; 61(1):119-21. PubMed ID: 8676148
[No Abstract] [Full Text] [Related]
5. Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
Muniz VP; Silva HC; Tsanaclis AM; Vainzof M
J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia.
Quane KA; Healy JM; Keating KE; Manning BM; Couch FJ; Palmucci LM; Doriguzzi C; Fagerlund TH; Berg K; Ording H
Nat Genet; 1993 Sep; 5(1):51-5. PubMed ID: 8220423
[TBL] [Abstract][Full Text] [Related]
7. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees.
Keating KE; Quane KA; Manning BM; Lehane M; Hartung E; Censier K; Urwyler A; Klausnitzer M; Muller CR; Heffron JJ
Hum Mol Genet; 1994 Oct; 3(10):1855-8. PubMed ID: 7849712
[TBL] [Abstract][Full Text] [Related]
8. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores.
Quane KA; Keating KE; Healy JM; Manning BM; Krivosic-Horber R; Krivosic I; Monnier N; Lunardi J; McCarthy TV
Genomics; 1994 Sep; 23(1):236-9. PubMed ID: 7829078
[TBL] [Abstract][Full Text] [Related]
9. Core myopathies and risk of malignant hyperthermia.
Klingler W; Rueffert H; Lehmann-Horn F; Girard T; Hopkins PM
Anesth Analg; 2009 Oct; 109(4):1167-73. PubMed ID: 19762745
[TBL] [Abstract][Full Text] [Related]
10. A mutation in the human ryanodine receptor gene associated with central core disease.
Zhang Y; Chen HS; Khanna VK; De Leon S; Phillips MS; Schappert K; Britt BA; Browell AK; MacLennan DH
Nat Genet; 1993 Sep; 5(1):46-50. PubMed ID: 8220422
[TBL] [Abstract][Full Text] [Related]
11. [Molecular pathology of malignant hyperthermia and central core disease].
Takagi A
Nihon Rinsho; 1997 Dec; 55(12):3307-14. PubMed ID: 9436456
[TBL] [Abstract][Full Text] [Related]
12. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
Lyfenko AD; Goonasekera SA; Dirksen RT
Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
[TBL] [Abstract][Full Text] [Related]
13. The role of the skeletal muscle ryanodine receptor (RYR1) gene in malignant hyperthermia and central core disease.
MacLennan DH; Phillips MS
Soc Gen Physiol Ser; 1995; 50():89-100. PubMed ID: 7676327
[No Abstract] [Full Text] [Related]
14. Ca2+ release channels of pigs heterozygous for malignant hyperthermia.
Shomer NH; Mickelson JR; Louis CF
Muscle Nerve; 1995 Oct; 18(10):1167-76. PubMed ID: 7659111
[TBL] [Abstract][Full Text] [Related]
15. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
Monnier N; Lunardi J
Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
[TBL] [Abstract][Full Text] [Related]
16. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
[TBL] [Abstract][Full Text] [Related]
17. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia.
Phillips MS; Khanna VK; De Leon S; Frodis W; Britt BA; MacLennan DH
Hum Mol Genet; 1994 Dec; 3(12):2181-6. PubMed ID: 7881417
[TBL] [Abstract][Full Text] [Related]
18. Mutation screening of dihydropyridine receptor gamma subunit cDNA from malignant hyperthermia susceptible patients.
Lynch PJ; Couch FJ; Gregg RG; Powers PA; Hogan K; McCarthy TV
Biochem Soc Trans; 1995 May; 23(2):352S. PubMed ID: 7672382
[No Abstract] [Full Text] [Related]
19. Luminal loop of the ryanodine receptor: a pore-forming segment?
Balshaw D; Gao L; Meissner G
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3345-7. PubMed ID: 10097041
[No Abstract] [Full Text] [Related]
20. Genetics of malignant hyperthermia.
Brandom BW
ScientificWorldJournal; 2006 Dec; 6():1722-30. PubMed ID: 17195870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
